secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001493152-24-046434
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi presents RTNova data supporting systemic targeting of metastatic lung cancer at IOVC and SITC
--------------------------------------------------------------------------------

- Data presented at IOVC and SITC shows RTNova enveloped virotherapy can target multiple metastatic tumor sites.
- RTNova uses tumor-selective vaccinia virus engineered to produce high levels of EEVs to avoid immune clearance.
- In an advanced lung metastasis model, RTNova demonstrated robust therapeutic potential as monotherapy and viral vector.
- The platform can induce expression of engineered payloads in tumor cells, enabling future delivery of therapeutic genes.
- Calidi plans to advance RTNova as a multi-modal systemic antitumor virotherapy and seek pharma collaborations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224046434/0001493152-24-046434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315224046434/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-046434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer